NLRP3 modulators

US10533005B2 · kind B2 · utility

Assignee

• Innate Tumor Immunity, Inc. · US

Inventors

• Gary D. Glick · Ann Arbor, US
• Shomir Ghosh · Brookline, US
• William R. Roush · West Jupiter, US
• Edward J. Olhava · Newton, US
• Daniel O'Malley · New Hope, US

Key dates

• Filing date: Feb 16, 2018
• Grant date: Jan 14, 2020
• Expiry date: Feb 16, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.